Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis

Vivak Parkash; Helen Ashwin; Shoumit Dey; Jovana Sadlova; Barbora Vojtkova; Katrien Van Bocxlaer; Rebecca Wiggins; David Thompson; Nidhi Sharma Dey; Charles L Jaffe; Eli Schwartz; Petr Volf; Charles J N Lacey; Alison M Layton; Paul M Kaye

doi:10.1038/s41591-024-03146-9

Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis

Vivak Parkash, Helen Ashwin, Shoumit Dey, Jovana Sadlova, Barbora Vojtkova, Katrien Van Bocxlaer, Rebecca Wiggins, David Thompson, Nidhi Sharma Dey, Charles L Jaffe, Eli Schwartz, Petr Volf, Charles J N Lacey, Alison M Layton, Paul M Kaye

Research output: Contribution to journal › Article › peer-review

Abstract

The leishmaniases are globally important parasitic diseases for which no human vaccines are currently available. To facilitate vaccine development, we conducted an open-label observational study to establish a controlled human infection model (CHIM) of sand fly-transmitted cutaneous leishmaniasis (CL) caused by Leishmania major. Between 24 January and 12 August 2022, we exposed 14 participants to L. major-infected Phlebotomus duboscqi. The primary objective was to demonstrate effectiveness of lesion development (take rate) and safety (absence of CL lesion at 12 months). Secondary and exploratory objectives included rate of lesion development, parasite load and analysis of local immune responses by immunohistology and spatial transcriptomics. Lesion development was terminated by therapeutic biopsy (between days 14 and 42 after bite) in ten participants with clinically compatible lesions, one of which was not confirmed by parasite detection. We estimated an overall take rate for CL development of 64% (9/14). Two of ten participants had one and one of ten participants had two lesion recurrences 4-8 months after biopsy that were treated successfully with cryotherapy. No severe or serious adverse events were recorded, but as expected, scarring due to a combination of CL and the biopsy procedure was evident. All participants were lesion free at >12-month follow-up. We provide the first comprehensive map of immune cell distribution and cytokine/chemokine expression in human CL lesions, revealing discrete immune niches. This CHIM offers opportunities for vaccine candidate selection based on human efficacy data and for a greater understanding of immune-mediated pathology. ClinicalTrials.gov identifier: NCT04512742 .

Original language	English
Number of pages	24
Journal	Nature Medicine
Early online date	2 Aug 2024
DOIs	https://doi.org/10.1038/s41591-024-03146-9
Publication status	E-pub ahead of print - 2 Aug 2024

Bibliographical note

Access to Document

10.1038/s41591-024-03146-9Licence: CC BY

s41591-024-03146-9
© The Author(s) 2024
Final published version, 10.2 MBLicence: CC BY

Cite this

Parkash, V., Ashwin, H., Dey, S., Sadlova, J., Vojtkova, B., Van Bocxlaer, K., Wiggins, R., Thompson, D., Dey, N. S., Jaffe, C. L., Schwartz, E., Volf, P., Lacey, C. J. N., Layton, A. M., & Kaye, P. M. (2024). Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis. Nature Medicine. Advance online publication. https://doi.org/10.1038/s41591-024-03146-9

@article{b7134fcc398443cdbd2de9f045ace4e6,

title = "Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis",

abstract = "The leishmaniases are globally important parasitic diseases for which no human vaccines are currently available. To facilitate vaccine development, we conducted an open-label observational study to establish a controlled human infection model (CHIM) of sand fly-transmitted cutaneous leishmaniasis (CL) caused by Leishmania major. Between 24 January and 12 August 2022, we exposed 14 participants to L. major-infected Phlebotomus duboscqi. The primary objective was to demonstrate effectiveness of lesion development (take rate) and safety (absence of CL lesion at 12 months). Secondary and exploratory objectives included rate of lesion development, parasite load and analysis of local immune responses by immunohistology and spatial transcriptomics. Lesion development was terminated by therapeutic biopsy (between days 14 and 42 after bite) in ten participants with clinically compatible lesions, one of which was not confirmed by parasite detection. We estimated an overall take rate for CL development of 64% (9/14). Two of ten participants had one and one of ten participants had two lesion recurrences 4-8 months after biopsy that were treated successfully with cryotherapy. No severe or serious adverse events were recorded, but as expected, scarring due to a combination of CL and the biopsy procedure was evident. All participants were lesion free at >12-month follow-up. We provide the first comprehensive map of immune cell distribution and cytokine/chemokine expression in human CL lesions, revealing discrete immune niches. This CHIM offers opportunities for vaccine candidate selection based on human efficacy data and for a greater understanding of immune-mediated pathology. ClinicalTrials.gov identifier: NCT04512742 .",

author = "Vivak Parkash and Helen Ashwin and Shoumit Dey and Jovana Sadlova and Barbora Vojtkova and {Van Bocxlaer}, Katrien and Rebecca Wiggins and David Thompson and Dey, {Nidhi Sharma} and Jaffe, {Charles L} and Eli Schwartz and Petr Volf and Lacey, {Charles J N} and Layton, {Alison M} and Kaye, {Paul M}",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = aug,

day = "2",

doi = "10.1038/s41591-024-03146-9",

language = "English",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis

AU - Parkash, Vivak

AU - Ashwin, Helen

AU - Dey, Shoumit

AU - Sadlova, Jovana

AU - Vojtkova, Barbora

AU - Van Bocxlaer, Katrien

AU - Wiggins, Rebecca

AU - Thompson, David

AU - Dey, Nidhi Sharma

AU - Jaffe, Charles L

AU - Schwartz, Eli

AU - Volf, Petr

AU - Lacey, Charles J N

AU - Layton, Alison M

AU - Kaye, Paul M

PY - 2024/8/2

Y1 - 2024/8/2

N2 - The leishmaniases are globally important parasitic diseases for which no human vaccines are currently available. To facilitate vaccine development, we conducted an open-label observational study to establish a controlled human infection model (CHIM) of sand fly-transmitted cutaneous leishmaniasis (CL) caused by Leishmania major. Between 24 January and 12 August 2022, we exposed 14 participants to L. major-infected Phlebotomus duboscqi. The primary objective was to demonstrate effectiveness of lesion development (take rate) and safety (absence of CL lesion at 12 months). Secondary and exploratory objectives included rate of lesion development, parasite load and analysis of local immune responses by immunohistology and spatial transcriptomics. Lesion development was terminated by therapeutic biopsy (between days 14 and 42 after bite) in ten participants with clinically compatible lesions, one of which was not confirmed by parasite detection. We estimated an overall take rate for CL development of 64% (9/14). Two of ten participants had one and one of ten participants had two lesion recurrences 4-8 months after biopsy that were treated successfully with cryotherapy. No severe or serious adverse events were recorded, but as expected, scarring due to a combination of CL and the biopsy procedure was evident. All participants were lesion free at >12-month follow-up. We provide the first comprehensive map of immune cell distribution and cytokine/chemokine expression in human CL lesions, revealing discrete immune niches. This CHIM offers opportunities for vaccine candidate selection based on human efficacy data and for a greater understanding of immune-mediated pathology. ClinicalTrials.gov identifier: NCT04512742 .

AB - The leishmaniases are globally important parasitic diseases for which no human vaccines are currently available. To facilitate vaccine development, we conducted an open-label observational study to establish a controlled human infection model (CHIM) of sand fly-transmitted cutaneous leishmaniasis (CL) caused by Leishmania major. Between 24 January and 12 August 2022, we exposed 14 participants to L. major-infected Phlebotomus duboscqi. The primary objective was to demonstrate effectiveness of lesion development (take rate) and safety (absence of CL lesion at 12 months). Secondary and exploratory objectives included rate of lesion development, parasite load and analysis of local immune responses by immunohistology and spatial transcriptomics. Lesion development was terminated by therapeutic biopsy (between days 14 and 42 after bite) in ten participants with clinically compatible lesions, one of which was not confirmed by parasite detection. We estimated an overall take rate for CL development of 64% (9/14). Two of ten participants had one and one of ten participants had two lesion recurrences 4-8 months after biopsy that were treated successfully with cryotherapy. No severe or serious adverse events were recorded, but as expected, scarring due to a combination of CL and the biopsy procedure was evident. All participants were lesion free at >12-month follow-up. We provide the first comprehensive map of immune cell distribution and cytokine/chemokine expression in human CL lesions, revealing discrete immune niches. This CHIM offers opportunities for vaccine candidate selection based on human efficacy data and for a greater understanding of immune-mediated pathology. ClinicalTrials.gov identifier: NCT04512742 .

U2 - 10.1038/s41591-024-03146-9

DO - 10.1038/s41591-024-03146-9

M3 - Article

C2 - 39095597

SN - 1078-8956

JO - Nature Medicine

JF - Nature Medicine

ER -